New MSF costing study in JAMA reveals dramatic markup on prices of new diabetes medicines and insulin pens
GLP-1 drugs (e.g. Ozempic) are sold at a nearly 40,000% markup in the US, but unavailable in low- and middle-income countries; and treating diabetes using insulin pen devices could be 30% less...